Identifying Treatments for Taste and Smell Disorders: Gaps and Opportunities. by Mainland, Joel D. et al.
Thomas Jefferson University 
Jefferson Digital Commons 
Department of Otolaryngology - Head and Neck 
Surgery Faculty Papers 
Department of Otolaryngology - Head and Neck 
Surgery 
10-9-2020 
Identifying Treatments for Taste and Smell Disorders: Gaps and 
Opportunities. 
Joel D. Mainland 
Linda A. Barlow 
Steven D. Munger 
Sarah E. Millar 
M. Natalia Vergara 
See next page for additional authors 
Follow this and additional works at: https://jdc.jefferson.edu/otofp 
 Part of the Otolaryngology Commons 
Let us know how access to this document benefits you 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Department of Otolaryngology - Head and Neck Surgery Faculty Papers by an authorized 
administrator of the Jefferson Digital Commons. For more information, please contact: 
JeffersonDigitalCommons@jefferson.edu. 
Authors 
Joel D. Mainland, Linda A. Barlow, Steven D. Munger, Sarah E. Millar, M. Natalia Vergara, Peihua Jiang, 
James E. Schwob, Bradley J. Goldstein, Shannon E. Boye, Jeffrey R. Martens, Donald A. Leopold, Linda M. 
Bartoshuk, Richard L. Doty, Thomas Hummel, Jayant M. Pinto, Casey Trimmer, Christine Kelly, Edmund A. 
Pribitkin, and Danielle R. Reed 
493
Chemical Senses, 2020, Vol 45, 493–502
doi:10.1093/chemse/bjaa038
Original Article
Advance Access publication 18 June 2020
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),  
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
© The Author(s) 2020. Published by Oxford University Press.
Original Article
Identifying Treatments for Taste and Smell 
Disorders: Gaps and Opportunities
Joel D. Mainland1, , Linda A. Barlow2, Steven D. Munger3, ,  
Sarah E. Millar4, M. Natalia Vergara5, Peihua Jiang1, James E. Schwob6, 
Bradley J. Goldstein7, Shannon E. Boye8, Jeffrey R. Martens3,  
Donald A. Leopold9, Linda M. Bartoshuk10, Richard L. Doty11,  
Thomas Hummel12, , Jayant M. Pinto13, Casey Trimmer14, Christine Kelly15, 
Edmund A. Pribitkin16 and Danielle R. Reed1
1Monell Chemical Senses Center, 3500 Market Street, Philadelphia, PA 19104, USA, 2Department of Cell & Developmental 
Biology, Rocky Mountain Taste and Smell Center, University of Colorado, Anschutz Medical Campus, Mail Stop 8108, 12801 
East 17th Avenue, Room L18-11121, Aurora, CO 80045, USA, 3Center for Smell and Taste, Department of Pharmacology and 
Therapeutics, 1200 Newell Drive, University of Florida, Gainesville, FL 32607, USA, 4Black Family Stem Cell Institute, Icahn 
School of Medicine at Mount Sinai, 1468 Madison Avenue, New York, NY 10029, USA, 5Department of Ophthalmology, Sue 
Anschutz-Rodgers Eye Center, University of Colorado School of Medicine, 1675 Aurora Court, Mail Stop F731, Aurora, 
CO 80045, USA, 6Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine, 
136 Harrison Ave., Boston, MA 02111, USA, 7Department of Head and Neck Surgery and Communication Sciences, Duke 
University School of Medicine, 40 Duke Medicine Cir Clinic 1F, Durham, NC 27717, USA, 8Department of Ophthalmology, 
University of Florida College of Medicine, 1600 SW Archer Road, Gainesville, FL 32610, USA, 9Division of Otolaryngology 
Head and Neck Surgery, University of Vermont Medical Center, 111 Colchester Avenue, Burlington, VT 05401, USA, 
10Department of Food Science and Human Nutrition, Center for Smell and Taste, University of Florida, 572 Newell Drive, 
Gainesville, FL 32607, USA, 11Smell and Taste Center and Department of Otorhinolaryngology: Head and Neck Surgery, 
Perelman School of Medicine, 3400 Spruce Street, University of Pennsylvania, Philadelphia, PA 19104, USA, 12Department 
of Otorhinolaryngology, Smell and Taste Clinic, Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden, 
Germany, 13Section of Otolaryngology—Head and Neck Surgery, Department of Surgery, The University of Chicago, 5841 
S. Maryland Avenue, MC 1035, Chicago, IL 60637, USA, 14Firmenich Inc., 250 Plainsboro Road, Plainsboro, NJ 08536, USA, 
15AbScent, 14 London Street, Andover, Hampshire  SP10 2PA, UK, and 16Department of Otolaryngology—Head and Neck 
Surgery, Thomas Jefferson University, 1020 Walnut Street, Philadelphia, PA 19107, USA
Correspondence to be sent to Joel D.  Mainland, Monell Chemical Senses Center, 3500 Market Street, Philadelphia,  
PA 10104, USA. e-mail: jmainland@monell.org
Editorial Decision 29 May 2020.
Abstract
The chemical senses of taste and smell play a vital role in conveying information about ourselves and 
our environment. Tastes and smells can warn against danger and also contribute to the daily enjoy-
ment of food, friends and family, and our surroundings. Over 12% of the US population is estimated to 
experience taste and smell (chemosensory) dysfunction. Yet, despite this high prevalence, long-term, 
effective treatments for these disorders have been largely elusive. Clinical successes in other sen-
sory systems, including hearing and vision, have led to new hope for developments in the treat-
ment of chemosensory disorders. To accelerate cures, we convened the “Identifying Treatments for 
Taste and Smell Disorders” conference, bringing together basic and translational sensory scientists, 
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dysfunction and next steps in a broad-based research strategy. Their suggestions for high-yield next 
steps were focused in 3 areas: increasing awareness and research capacity (e.g., patient advocacy), 
developing and enhancing clinical measures of taste and smell, and supporting new avenues of re-
search into cellular and therapeutic approaches (e.g., developing human chemosensory cell lines, 
stem cells, and gene therapy approaches). These long-term strategies led to specific suggestions for 
immediate research priorities that focus on expanding our understanding of specific responses of 
chemosensory cells and developing valuable assays to identify and document cell development, re-
generation, and function. Addressing these high-priority areas should accelerate the development of 
novel and effective treatments for taste and smell disorders.
Key words:  cell culture, olfaction, sniff
Introduction
Over 12% of the US population is estimated to experience taste or 
smell (chemosensory) dysfunction (Hoffman et al. 2016). The chem-
ical senses of taste and smell play a vital role in conveying informa-
tion about ourselves and our environment. They help identify dangers 
(e.g., the taste of rancid food and the smell of smoke) and contribute 
to the daily enjoyment of our food, our friends and family, and our 
surroundings. Although the loss of taste or smell is not a fatal condi-
tion, it affects numerous aspects of human health and has a significant 
effect on quality of life (Croy et al. 2014; Philpott and Boak 2014; 
Rawal et al. 2014; Hoffman et al. 2016; Erskine and Philpott 2020).
Chemosensory disorders vary both in their cause and in their con-
sequences for smell or taste functions. Smell disorders are typically 
divided into 4 categories based on their impact on odor perception. 
Anosmia is the absence of smell perception, whereas hyposmia indi-
cates a measurably reduced ability to perceive smells. Parosmia is a dis-
tortion of smell in which the perceived quality of the smell differs from 
what it “should” be (e.g., a rose smells like burning rubber). Patients 
with phantosmia perceive smells even when the odor itself is not pre-
sent. There are analogous taste disorders, including ageusia (lack of 
taste function), hypogeusia (reduced taste perception), dysgeusia/
parageusia (distorted taste), and phantogeusia (taste phantoms).
Many factors may damage the olfactory or taste systems and re-
duce function. These factors include trauma, surgical damage, age, 
bacterial and viral illness, chronic rhinosinusitis, severe allergies, 
cancer treatments, neurological diseases and disorders, inborn gen-
etic disorders, and some medications (Hummel et al. 2011, 2017). In 
many cases, the cause of the smell or taste impairment is unknown 
(idiopathic). Smell disorders resulting from conductive issues, such as 
nasal polyps, are often treatable with surgical and medical interven-
tions, for example, nasal steroids (Yan et al. 2019). However, biologic 
therapies for diseases such as nasal polyps are on the horizon (Pinto 
et al. 2019). Smell training, which involves repeated exposure to odors 
over weeks or months, is also helpful in some cases (Sorokowska et al. 
2017). However, effective treatment interventions are often lacking 
(Doty 2019). Thus, the search for treatments is important to public 
health. With this need in mind and with the support of the National 
Institute on Deafness and Other Communication Disorders (NIDCD; 
R13 DC017387), 3 major US research centers focused on the chem-
ical senses (the Monell Center, the Rocky Mountain Taste and Smell 
Center, and the University of Florida Center for Smell and Taste) or-
ganized a workshop in November of 2018 to bring together basic and 
translational sensory scientists, health care professionals, and individ-
uals who have experienced a taste or smell disorder to discuss research 
opportunities to advance/translate targeted molecular approaches into 
clinical applications and treatments.
Although our understanding of taste and smell disorders is 
advancing, participants at the conference identified gaps in scientific 
knowledge and lack of research capacity, as well as new and innovative 
research approaches that could facilitate the march toward potential 
therapies. In addition, participants recognized that the studies of treat-
ments for smell and taste dysfunction comprised a small percentage of 
ongoing research and would benefit from increased numbers of investi-
gators with training in regenerative medicine entering this scientific area.
In what follows, we summarize the presentations and discussions 
at the “Identifying Treatments for Taste and Smell Disorders” con-
ference and outline gaps in our current understanding of chemo-
sensory disorders identified by the conference participants. We also 
discuss potential broad-based research strategies aimed at increasing 
awareness and research capacity, as well as specific suggestions for 
immediate research priorities to increase the pace of research, espe-
cially in areas likely to lead to therapies.
Chemosensory disorders
The “Identifying Treatments for Taste and Smell 
Disorders” conference
Ninety-four scientists, clinicians, and patients from around the world 
convened at the University City Science Center in Philadelphia, PA, 
on November 14 and 15, 2018. The conference was divided into 4 
sessions that involved lectures and discussions (Table 1). Organizers 
met at the conclusion of the meeting to discuss the major themes and 
potential action items identified over the 2 days.
Session I: Stem cell therapies 
The first session focused on stem cells in sensory organs for smell, 
taste, vision, and balance; the roles of stem cells in normal tissue de-
velopment and regeneration; and the potential uses of stem cells in 
modeling complex sensory tissues or in disease therapies (e.g., Ren 
et al. 2014; Vergara et al. 2017; Gaillard et al. 2019; Kurtenbach 
et al. 2019; Peterson et al. 2019; Sayyid et al., 2019).
Session II: Gene therapies 
The second session focused on gene therapy strategies in hearing, vi-
sion, and smell (e.g., Gao et al. 2018; Green et al. 2018; McCullough 
et  al. 2019). Gene therapies have shown early success in treating 
some sensory disorders resulting from single-gene mutations, such as 
a form of retinitis pigmentosa (Beltran et al. 2012).
Session III: Clinical research 
On the second day of the conference, patients joined the audience to 
hear about the latest in clinical research focused on smell and taste 
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disorders (e.g., Snyder and Bartoshuk 2016; Hummel et  al. 2017; 
Bainbridge et al. 2018; Doty 2019; Liu et al. 2019).
Session IV: Patient engagement 
The final session centered on individuals affected by smell or taste 
disorders. The session began with a patient-focused summary of 
the science presented earlier in the conference and a discussion of 
the challenges that come with navigating the US health system. 
Importantly, patients and patient advocates shared stories about 
their own experiences with chemosensory disorders and about ways 
to engage members of this patient community.
Our current understanding of chemosensory 
disorders
The field has made recent progress toward developing methods for 
quantifying chemosensory dysfunction and establishing definitions of 
impairment and improvement (Hummel et al. 2017). Yet, despite this 
progress, many basic questions about taste and smell disorders have 
yet to be answered. For example, we do not know how to consistently 
regrow human olfactory neurons or taste receptor cells after injury (e.g., 
head trauma from sports), illness (e.g., upper respiratory tract infec-
tions), or how to reconnect these cells to brain areas that give rise to 
perception. We do not know how to prevent smell loss after colds, flu or 
COVID-19, or even why some viral or bacterial infections lead to smell 
loss and others do not. We do not understand why some people are born 
without a sense of smell or taste, except in a few rare instances where 
genetic mutations have been identified (Smith et al. 1965; Pearson et al. 
1970; Wolfe and Henkin 1970; Gadoth et al. 1997; Feldmesser et al. 
2007; Weiss et al. 2011; Hanchate et al. 2012; Karstensen et al. 2015; 
Alkelai et al. 2016; Boesveldt et al. 2017; Uytingco et al. 2019). Even 
in cases where these congenital genetic causes are known, the cures are 
not. We have no immortalized cell lines for human taste receptor cells 
or olfactory sensory neurons, so regeneration is hard to study except in 
bulk tissue or animal models. This lack of knowledge points to a need 
for greater efforts to answer these questions.
Suggestions for high-yield next steps
The next steps identified by conference participants involve mar-
shaling the resources to support a more vigorous research ef-
fort—both in basic research and in translational studies—to bring 
discoveries from bench to bedside. The 7 suggestions (Table  2) 
gathered at the conference fall under the general categories of 
1)  supporting new avenues of research into cellular approaches, 
2)  developing and enhancing clinical measures of taste and smell, 
and 3)  increasing awareness and research capacity. Each of these 
suggestions is discussed below, followed by the specific research pri-
orities that these suggestions indicate.
Support new avenues of research into cellular 
approaches
Understanding the development, degeneration, and regeneration of 
taste and smell tissues at the cellular level is necessary to identify 
sources of sensory dysfunction and to develop treatments to address 
them. Increasing our focus on cross-cutting basic principles of sen-
sory regeneration that apply broadly to sensory systems will also 
expand our capacity to develop treatment strategies.
Cultivate human olfactory and taste cell lines, as well as 
organoids 
A major reason taste and smell are difficult to study is because one of 
the tools used in other sensory systems is missing: immortalized cell 
lines for olfactory sensory neurons and taste receptor cells, particu-
larly of human origin. Investigators have made inroads in primary 
culture of taste cells (Ozdener and Rawson 2011, 2013; Ozdener 
et al. 2012) but have not developed immortalized cell lines that are 
easily shared among research laboratories or that fully recapitu-
late native cell phenotypes. Progress has also been made in the pri-
mary culture of human olfactory stem cells and their differentiation 
into olfactory sensory neurons, for example, culture expansion of 
de-differentiated murine basal cells (Goldstein et al. 2016). These ol-
factory stem cells are being transplanted into model hosts (e.g., mice 
and rats) to test their ability to recolonize olfactory tissues (Peterson 
Table 1. Presentations at the “Identifying Treatments for Taste and Smell Disorders” Conference, November 14–15, 2018
Speaker Affiliation Talk title
Session I: Stem cell therapies (Chair: Danielle Reed, Monell Center)
Sarah Millar University of Pennsylvania Wnt signaling in taste papilla development, stem cells, and regeneration
Alan Cheng Stanford University Regeneration of sensory hair cells in the inner ear balance organs
Natalia Vergara University of Colorado Denver 3D retinal organoids: new frontiers for regenerative therapies in the eye
Linda Barlow University of Colorado Denver Taste cell renewal and cancer therapies
Peihua Jiang   
James Schwob
Monell Center   
Tufts University
Stem cells in the taste bud   
A potential strategy for fixing a broken nose
Bradley Goldstein Duke University Olfactory stem cells in the clinic
Session II: Gene therapies (Chair: Linda Barlow, University of Colorado, Denver)
Jeffrey Holt   
Shannon Boye
Harvard University   
University of Florida
Gene therapy in cochlea   
Gene therapies for GUCY2D-associated retinal disease
Jeffrey Martens University of Florida Gene therapeutic rescue of congenital olfactory dysfunction
Session III: Clinical Research (Chair: Joel Mainland, Monell Center)
Donald Leopold   
Linda Bartoshuk
University of Vermont   
University of Florida
Smell disorders   
Taste damage: causes, assessment, treatment
Richard Doty University of Pennsylvania Clinical assessment of chemosensory disorders in the U.S.
Thomas Hummel Dresden University Clinical assessment of chemosensory disorders in Germany
Jay Pinto University of Chicago Epidemiological studies of chemosensory disorders
Session IV: Patient Engagement (Chair: Steven Munger, Unversity of Florida)
Casey Trimmer Firmenich Summary of the scientific sessions for patients
Chris Kelly AbScent Patients together on the web: internet resources for chemosensory loss
Edmund Pribitkin Thomas Jefferson University Navigating the U.S. health system
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et al. 2019). A primary cell culture approach can be used to identify 
signaling pathways, molecular targets, and compounds that force ol-
factory stem cell activation and neurogenesis and, thereby, exploit 
the endogenous capacity of the resident stem cells of the olfactory 
epithelium. However, primary cultures may differ from native cells 
in form and/or function due to their altered environment and the im-
pact of the manipulations needed to culture them. Primary cultures 
also have a limited lifespan, so  immortalized cell lines would be a 
useful complement, hastening the pace of discovery. For example, 
immortalized human olfactory cells could be more easily screened in 
high-throughput systems to identify compounds that would impact 
cell growth, augment odor responsiveness, or confer resistance to 
pathogens.
Likewise, taste regeneration is difficult to study in this manner be-
cause there are no available immortalized cells. However, alternative 
strategies are being developed. For example, taste cell organoids—
specially grown aggregations of taste receptor cells derived from 
adult taste stem cells that mimic many qualities of taste buds— are 
one alternative to immortalized cell lines (Ren et al. 2014; Barlow 
2015; Clevers 2016). Taste receptor cell organoids have cell–cell 
interactions that are especially important for taste cells and, thus, 
may replicate disease pathology better than traditional cell cultures 
(Ren et al. 2017). To date, however, no human taste cell organoids 
have been reported, and the development of both organoid and im-
mortalized taste cell lines would offer significant advantages for de-
veloping new therapeutic strategies.
Focus on cross-cutting basic principles of sensory regeneration 
Harnessing new advances in regenerative medicine, especially those 
for other sensory systems, is a key pillar in developing treatment 
strategies for taste and smell disorders. Therefore, an objective of 
this conference was to invite scientists working on regeneration 
and therapy in other sensory modalities to learn from their work. 
They described gene-editing methods to treat single-gene mutations 
that lead to deafness or blindness (Gyorgy et al. 2019; McCullough 
et al. 2019), retinal organoid cultures to learn about development 
and regeneration (Aasen and Vergara 2020), and viral vectors to re-
store retinal function and useful vision (Gamlin et al. 2019). Similar 
viral-based gene therapy approaches are also showing promise in re-
storing auditory or olfactory dysfunctions related to single gene mu-
tations (McIntyre et al. 2012; Williams et al. 2017; Gao et al. 2018).
Decades of studies in cell signaling and development in taste and 
smell tissues have been crucial in identifying chemical-sensing path-
ways and molecules, and research with specific olfactory and gusta-
tory progenitor cells is just beginning to yield results. For instance, 
the core Wnt/β-catenin signaling pathway in stem cells contributes 
to many sensory systems, including hearing (Jansson et  al. 2019) 
and taste (Gaillard et al. 2015). For olfaction, intranasal stem cell 
infusion has been at least partially successful at establishing olfac-
tory receptors in mice with hyposmia (Kurtenbach et al. 2019).
Recent progress in these and other areas suggest that taste and 
olfactory researchers not only will benefit from work in vision and 
hearing, but also may lead the way in certain areas of regenerative 
medicine. Benefits may accrue from focusing on the similarities 
among sensory systems rather than the differences. If we focus too 
much on the unique properties among sensory systems, we may miss 
basic principles that will increase the pace of multiple fields. Thus, 
the “Identifying Treatments for Taste and Smell Disorders” confer-
ence represents a valuable step toward developing strong collabor-
ations in regenerative medicine across the sensory fields.
Develop and enhance clinical measures of taste 
and smell
Chemosensory loss precedes cognitive deficits in Alzheimer’s diseases 
(Doty and Hawkes 2019), tremors in Parkinson’s disease (Doty and 
Hawkes 2019), and cough or fever in COVID-19 (Haehner et  al. 
2020). Yet, in all of those cases, we learned that the chemosensory 
loss was associated with the disease well after we learned about the 
nonchemosensory associations. This is due to a lack of widespread 
chemosensory testing. In the United States, newborns are screened 
for hearing before they leave the hospital and vision is checked at 
primary care appointments to coincide with visual development. In 
contrast, there is no widespread testing for olfactory function in the 
general population. In a 2007 survey in the United Kingdom, 97% of 
consultant otorhinolaryngologists managed olfactory dysfunction, 
but only 45% formally tested for chemosensory impairment and 
only 12% did so routinely (McNeill et al. 2007). Fewer than 25% 
of individuals with smell dysfunction are aware of their sensory def-
icit until formally tested (Doty 2017) and children with congenital 
smell loss are typically unaware of the dysfunction until they are 
over 10 years old (Temmel et al. 2002). Widespread testing would 
enhance disease diagnosis, aid patients in identifying and addressing 
chemosensory dysfunction, and help identify the mechanistic under-
pinnings of disease (Weiss et al. 2011).
Build capacity in the analysis of electronic health records and 
other large-scale data 
Although electronic medical health records contain vast amounts 
of data, we lack standardized methods to measure taste and smell 
dysfunction across clinical settings, making such information more 
difficult to analyze. Without such standardized methods, we are lim-
ited in our ability to identify early chemosensory impairments as 
self-report of taste and smell function is poorly correlated with ob-
jective tests (Landis et al. 2003). Even when patients present with 
such impairments, we lack cost-effective ways to evaluate the struc-
tural or physiological changes in olfactory or taste tissues underlying 
Table 2. Consensus recommendations identified by conference participants
General category Seven suggestions for high-yield next steps
Support new avenues of research into cellular approaches 1. Cultivate human olfactory and taste cell lines, as well as organoids
2. Focus on cross-cutting basic principles of sensory regeneration
Develop and enhance clinical measures of taste and smell 3. Build capacity in the analysis of electronic health records and other large-scale data
4. Disseminate methods to measure taste and smell dysfunction in a clinical setting
5. Develop new and cost-effective ways to evaluate dysfunction in chemosensory systems
Increase awareness and research capacity 6. Encourage the formation of patient advocacy groups
7. Train scientists in both stem cell and chemosensory biology
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these chemosensory deficits or to assess their response to treatment 
as their sensory capacity recovers.
Analysis of the storehouse of data found in electronic health re-
cords has the potential to find new connections between chemosen-
sory dysfunction and recovery. These data are an underutilized source 
of information about the natural history of taste and smell dysfunc-
tion and could be used to understand what patient characteristics are 
most often associated with a particular type of chemosensory disorder. 
These types of analysis do not rely on assumptions or prior knowledge 
about the diseases and conditions and, thus, can identify connections 
that are missed by traditional types of chart review studies. For ex-
ample, a recent study found that olfactory loss is a stronger predictor 
of 5-year mortality rate than heart failure (Pinto et al. 2014). The long 
observation periods spanned by electronic medical records—poten-
tially from birth to death—and large sample sizes make these data-
bases particularly useful for research on factors associated with rare 
outcomes like certain types of chemosensory disorders.
Other very large data sets are being generated that can expand 
the understanding of the etiology and treatment of chemosen-
sory disorders. Some examples are the UK Biobank (Sudlow et  al. 
2015), the Million Veteran Program (Gaziano et  al. 2016), and All 
of Us (Precision Medicine Initiative Working Group, 2015), which 
are large-scale efforts to study hundreds of thousands to millions of 
people through health records, surveys, blood draws, and other med-
ical tests, as well as genetic data. These data sources have the potential 
to further inform us about the natural history of taste and smell dys-
function and factors associated with recovery. In the United States, the 
National Health and Nutrition Examination Survey (NHANES) now 
incorporates questions related to smell and taste alterations, offering 
yet another resource for querying population data (Rawal et al. 2015; 
Hoffman et al. 2016; Gallo et al. 2020). When deciding among the 
available tests to use in large surveys, consider using a test with high 
reliability coefficients and, when possible, a test that has previously 
been used in other large surveys to aid in comparison across studies.
Disseminate methods to measure taste and smell dysfunction in 
a clinical setting 
A number of sensitive, practical, and well-validated standardized ol-
factory and gustatory tests have been developed, some with National 
Institutes of Health (NIH) funding, and are commercially avail-
able. Unfortunately, although they are used in academia and in a 
number of otorhinolaryngology and neurology clinics, their more 
widespread use has been limited due to lack of physician knowledge 
and insurance reimbursement. The best known commercially avail-
able olfactory tests are the Sniffin’ Sticks test (Kobal et  al. 1996), 
the self-administered University of Pennsylvania Smell Identification 
Test, and the Brief Smell Identification Test (Doty et al. 1984, 1996), 
the Japanese T&T olfactometer (Toyota et al. 1978), the NHANES 
Pocket Smell Test (Rawal et al. 2015; Liu et al. 2016), and the NIH 
Tool-Box test (Coldwell et al. 2013; Dalton et al. 2013). Some of 
these tests can be self-administered, so they are practical in clinical 
settings and, in some cases, can be sent through the mail. Additional 
clinical tests are also in various stages of development (Hsieh et al. 
2017; Douglas et al. 2018; Doty et al. 2019).
Develop new and cost-effective ways to evaluate dysfunction in 
chemosensory systems 
Current research and clinical evaluations of taste and smell are ham-
pered by the lack of diagnostic tools that can distinguish the site and 
type of dysfunction, whether it be  from peripheral tissue damage, 
nerve degeneration, or disruptions to central processing.
Other than an inspection for signs of inflammation, there are few 
or no methods to judge the health of the taste or smell receptor cells 
and supporting tissue. Although biopsies are possible for both tissue 
types and are routinely done for research purposes (Rawson et al. 
1998; Spielman et al. 2010), they are too invasive to be part of a 
routine medical exam. Similarly, recent models for nasal airflow may 
help clinicians predict surgery outcomes but are not yet at a point 
where they can be used in routine clinical work (Li et al. 2018).
An additional difficulty is determining if healthy nerves 
connect peripheral olfactory or taste tissues to the brain. 
Electroencephalograms can measure responses at the olfactory bulb 
(Iravani et al. 2020), fMRI methods can evaluate how the brain re-
sponds to tastes and odors (e.g., Bao et al. 2016; Iannilli et al. 2019), 
and intracranial electroencephalograms can assess olfactory func-
tion but would typically only be employed in patients with medically 
resistant epilepsy (Zelano et al. 2016; Jiang et al. 2017). However, 
even if medically warranted, most of these techniques are expensive, 
time consuming, and rarely, if ever, are part of the standard medical 
evaluation of chemosensory dysfunction.
An emphasis on new diagnostic methods to assess the health of 
smell and taste tissue is critical because therapies cannot be gener-
ated without identifying the source of the problem. For instance, 
growth factors may be required to stimulate the reconnection of 
axons running through the cranium in cases where smell impair-
ment arises from damage to the olfactory nerve. This is a different 
strategy than the one that is needed for someone born without an 
olfactory bulb.
The fluids relevant to each tissue type (saliva in the case of taste 
and mucus in the case of smell) are also critical for chemosensory 
function. However, there has been little progress in analyzing these 
fluids for biomarkers related to inflammation or cellular dysfunction 
(e.g., Yoshikawa et al. 2018). Researchers can measure inflammation 
markers in nasal mucus using specialized tests (Pearlman 1999), but 
no test is available for routine clinical testing.
Measures of tissue health or damage are also critical for 
evaluating the progress of therapies. Although the restoration of sen-
sory function is the goal and, thus, the ultimate measure of improve-
ment, the effects of technologies, such as stem cell therapy and gene 
therapy, will likely be incremental. We need objective measures of 
tissue and organ restoration to tell investigators, and ultimately clin-
icians, that they are headed in the right direction even before patients 
experience a noticeable improvement in their sensory ability.
Increase awareness and research capacity
Increasing awareness of the devastating effects of taste or smell 
dysfunction can garner public and financial support, a funda-
mental requirement for significant research to continue. It also 
brings greater awareness to researchers in related fields and to 
newly developing researchers, making collaborations and special-
izations in these fields more likely, which will increase the pace of 
discovery.
Encourage the formation of patient advocacy groups 
One path for commanding more research capacity is the use of pa-
tient groups as advocates to contribute to public awareness and 
elicit public and financial support. Patients can become advocates 
and provide expert knowledge and insights into the needs of people 
living with chemosensory disorders. These advocates can be key 
communicators between researchers, funders, and patients on the 
needs for and results of research into their conditions. Indeed, advo-
cacy groups, such as the National Federation for the Blind and the 
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Hearing Loss Association for America, have been critical advocates 
for sensory disorders. Similarly, charities such as AbScent (abscent.
org/), Fifth Sense (fifthsense.org.uk), and Reuksmaakstoornis 
(https://reuksmaakstoornis.nl/) have emerged to begin to fill this gap. 
Patient support groups served through websites and social media 
allow advocacy groups to reach large audiences. These groups may 
take on even more international importance with the emergence of 
chemosensory loss as a symptom of COVID-19 (Pellegrino et  al. 
2020). Due to national differences in legal requirements for charities 
and other nonprofit groups, distinct or affiliate advocacy groups will 
likely need to emerge in each country.
Patient advocates can serve on scientific advisory boards, partici-
pate in scientific workshops, and give interviews and presentations 
about their experience of smell or taste dysfunction. Patient groups 
can increase the speed of research and discovery by advocating at 
local, state, federal, and international levels for additional funding. 
They can also increase research capacity, for example, by organizing 
registries of people who have taste and/or smell dysfunction who 
would like to take part in research that would give clinical insights 
into their disease.
Being private citizens with taste or smell dysfunction gives these 
advocates credibility with those who allocate research funds. The 
very formation of the NIDCD, the US National Institutes of Health’s 
institute devoted in part to the study of deafness and other commu-
nication disorders (including smell and taste), is an example of the 
power of focused patient advocacy (National Institute on Deafness 
and Other Communication Disorders 2019). Patient advocates can 
also advise on how to communicate with other patients about the re-
search being done, combating the idea that no one cares and nothing 
is happening. One example where patient advocacy groups may 
serve an important role is to work with clinicians to establish insur-
ance reimbursement for routine and specialized care for the sense of 
taste and smell, a current practical gap in the clinical care of people 
with chemosensory problems.
Train scientists in both stem cell and chemosensory biology 
Human embryonic and induced pluripotent stem cells (Thomson 
et al. 1998; Takahashi et al. 2007) have the potential to transform 
not only our understanding of taste and smell disorders but also our 
approaches to treating these conditions, and the pace of developing 
new knowledge about stem cell biology has been frenetic. These 
cells are a path forward to establish models of taste and smell de-
velopment and provide an opportunity to design platforms 1)  for 
discovery, to find drugs that increase taste receptor cell or olfactory 
sensory neuron numbers, and 2) for predictive toxicology, identifying 
chemicals that are especially toxic to taste and smell receptors and 
cells, for example, the thyroid treatment methimazole (Hallman and 
Hurst 1953; Genter et al. 1995; Clark et al. 2015). Most important, 
pluripotent stem cells represent a source of cells for therapies to treat 
patients with taste and smell disorders.
The translation of the remarkable potential of stem cells 
into practice is dependent on the ability of scientists to direct 
the differentiation of immature cells to the desired cell type(s). 
Therefore, the field needs scientists who not only are trained in 
stem cell biology but also have expertise in chemosensory biology, 
so that they can understand the progression of immature cells 
into fully differentiated taste and olfactory receptor cell types. 
Thus, training programs that integrate stem cell and chemosen-
sory biology are needed. Few existing laboratories study taste and 
smell regeneration, but these rare laboratories provide a valuable 
foundation on which to build training programs. The ultimate aim 
is to increase the pipeline of scientists and the number of estab-
lished laboratories that are especially important resources for this 
future growth. One practical step to attract students and early-
career scientists into this field would be to add symposia at stem 
cell biology conferences on chemosensory biology that would at-
tract the attention of both developing and established researchers. 
Alternatively, symposia focused on stem cell biology can be in-
cluded at chemosensory research conferences, such as the annual 
meeting of the Association for Chemoreception Sciences and the 
European Chemoreception Research Organization.
There is also a need for more clinician-scientists trained in 
otolaryngology who can evaluate patients, collect tissue, and pro-
vide leadership in translational research using stem cells, gene 
therapy, or other therapeutic approaches. Substantially increased 
efforts are essential to increase exposure to chemosensory dis-
orders into predoctoral and graduate medical education and into 
specialty training in otolaryngology at all levels. Of particular 
need is exposure to the impact of smell and taste disorders on pa-
tients, improved clinical care for those affected by these disorders, 
and increased translational and clinical research in these areas. 
Strategies to increase participation by otolaryngologists and other 
clinician-scientists more broadly in the study and treatment of 
smell and taste disorders could include direct engagement with 
relevant medical licensing groups and professional societies that 
impact the content of medical curricula and training of specialists 
in otolaryngology.
Specific suggestions for research priorities
These preceeding  7 suggestions for high-yield next steps, aimed 
at increasing awareness and research capacity, developing and 
enhancing clinical measures of taste and smell, and supporting new 
avenues of research into cellular approaches, lead to specific research 
priorities. The  following  suggestions are aimed at expanding our 
knowledge of the development, degeneration, and regeneration of 
taste- and smell-related cells, as well as developing valuable assays 
to identify and document these cellular effects, to clear the way for 
regenerative approaches to treat taste and smell dysfunction.
Increase knowledge of specific responses of  
taste- and smell-related cells
Restoration of smell and taste function through the regeneration of 
lost or damaged olfactory and taste receptor cells is a key aim of the 
research strategy to address taste and smell dysfunction. However, 
although restoration/repair of the olfactory and taste cells is a focal 
point, it is likely that relevant molecular triggers and signals in-
volve a much broader cellular landscape that includes support cells, 
progenitor cells, and other key factors. In addition, the brain must 
correctly decode the signals provided by the receptors themselves. 
Research leading to treatments for chemosensory dysfunction must 
be supported by a strong research program to identify all these rele-
vant factors.
Systems approaches to comprehensive olfactory and taste  
cell-specific data sets 
Using “omic” approaches (e.g., genomics and metabolomics) can 
identify the vast array of transcripts, proteins, and pathways in-
volved in normal capacity for taste and smell, as well as markers of 
disease related to chemosensory regeneration (Moyer et  al. 2009; 
Nickell et al. 2012; Ibarra-Soria et al. 2017; Sukumaran et al. 2017; 
Brann et al. 2020).







se/article/45/7/493/5859521 by guest on 24 D
ecem
ber 2020
Immunological and cytotoxic responses 
Many cases of taste and smell impairment result from immuno-
logical responses to disease, or the cellular responses to cytotoxic 
treatments, such as those used in chemotherapy. Identifying these 
responses in mammalian sensory cells will identify markers and 
targets for approaches to chemosensory regeneration (Wang et  al. 
2009; Cohen et al. 2016).
Characterization of cell cycle and differentiation 
Cell growth and development are central to healthy and diseased 
chemosensory tissues (Vermeulen et al. 2003). Characterizing these 
processes as they directly relate to the identification and propagation 
of stem cell populations will be key to taste and smell regeneration.
Develop assays to identify and document cell 
development
In tandem with expanding our knowledge of specific responses of 
taste- and smell-related cells, we need to develop assays that will 
identify and document these aspects of cell development and key 
biomarkers in cell degeneration and regeneration, as well as meas-
urements for sustainability of tissue transplantation. This would not 
only support research to address taste and smell dysfunction but also 
may be developed into clinical tools to allow us to identify problems 
and measure outcomes.
High-throughput assays 
Processing of large numbers of samples across a wide range of pa-
tients and subjects is necessary to discover novel cellular signals 
(pathways) that affect stem cell behavior in sensory cell regeneration 
(Discher et  al. 2009). Development of high-throughput assays for 
this purpose will be necessary to accomplish this monumental task.
Small-molecule screens 
Historically, small-molecule screens have identified useful ligands 
for modulating stem cell fate and developmental signaling path-
ways related to tissue degeneration and regeneration (Ding and 
Schultz 2005).
Assays to assess transplantation 
To evaluate feasibility and sustainability of transplanted taste and 
smell progenitor cells, we need to develop assays to monitor these 
processes. This is necessary not only to develop techniques to address 
taste and smell dysfunction but also to evaluate patients for poten-
tial transplantation and to follow the outcomes of the treatment as 
it progresses.
Summary
The conference on “Identifying Treatments for Taste and Smell 
Disorders” brought together basic and translational sensory scien-
tists, health care professionals, patients, and patient advocates who 
indicated the gaps in our current understanding of chemosensory 
disorders and suggest next steps to hasten our pace of discovery of 
treatments for these often debilitating conditions. They identified 7 
high-yield next steps, aimed at increasing awareness and research cap-
acity, developing and enhancing clinical measures of taste and smell, 
and supporting new avenues of research into cellular approaches. 
These broad-based strategies led to 6 specific suggestions for imme-
diate research priorities that will 1) expand understanding of specific 
responses of taste- and smell-related cells and 2)  develop valuable 
assays to identify and document cell development. Marshaling the 
resources to support a more vigorous research effort, both in basic 
research and in early- and later-stage translational studies, will lead 
to new and innovative approaches toward identifying patients with 
taste and smell disorders, the sources of those impairments, and 
advancing and monitoring potential therapies to mitigate their effects. 
These high-priority research areas, if addressed, will greatly improve 
the identification and treatment of taste and smell disorders. Such a 
commitment to bringing taste and smell research funds and focus to 
parallel those of sight and hearing is overdue.
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